良性黑色素瘤患者使用咪喹莫特乳膏治疗的预后标志物：一项长期随访研究。
Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
机构信息
Department of Dermatology, University of Bern, Bern, Switzerland.
Department of Dermatology, University of Bern, Bern, Switzerland.
出版信息
J Am Acad Dermatol. 2016 Jan;74(1):81-87.e1. doi: 10.1016/j.jaad.2015.08.031. Epub 2015 Oct 23.
BACKGROUND
More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).
OBJECTIVE
We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.
METHODS
This was a single-arm, open-label, nonrandomized, prospective study.
RESULTS
Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.
LIMITATIONS
Our study was a single-center, nonrandomized study.
CONCLUSION
An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.
背景
需要更多数据来确定咪喹莫特治疗恶性雀斑样痣（LM）后长期成功的预测因素。
目的
我们旨在确定接受咪喹莫特治疗的 LM 患者无复发生存的人口统计学、临床和组织学预后标志物。
方法
这是一项单臂、开放标签、非随机、前瞻性研究。
结果
我们的研究纳入了 89 例组织学证实的 LM 患者，在接受咪喹莫特治疗后中位随访时间为 4.8 年。16 例患者（18%）复发。局部复发风险增加的统计学显著指标包括：黑素细胞总数、基底层和棘细胞层黑素细胞数量以及 pagetoid 扩散黑素细胞数量。
局限性
我们的研究是一项单中心、非随机研究。
结论
在诊断基线活检标本中评估不同黑素细胞分数可能有助于预测 LM 对咪喹莫特治疗的反应。
Zotero 插件